Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the business’s stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $68.96, for a total value of $27,584.00. Following the transaction, the vice president now owns 80,145 shares of the company’s stock, valued at approximately $5,526,799.20. This trade represents a 0.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Thursday, March 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00.
• On Thursday, February 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $59.54, for a total transaction of $23,816.00.

ANI Pharmaceuticals Stock Up 0.9 %

Shares of ANIP opened at $68.72 on Tuesday. The business’s 50 day simple moving average is $62.52 and its 200-day simple moving average is $59.15. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $70.00. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of -124.95 and a beta of 0.49.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ANIP. Jefferies Financial Group initiated coverage on ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a “buy” rating and a $80.00 price target for the company. StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, April 8th. JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price target on the stock. Guggenheim reaffirmed a “buy” rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Friday. Finally, HC Wainwright reissued a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $79.75.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Millennium Management LLC increased its holdings in shares of ANI Pharmaceuticals by 89.3% in the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock worth $55,437,000 after buying an additional 473,097 shares during the last quarter. JPMorgan Chase & Co. grew its position in ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after acquiring an additional 340,854 shares in the last quarter. abrdn plc purchased a new position in ANI Pharmaceuticals in the fourth quarter worth about $13,155,000. Deep Track Capital LP increased its stake in ANI Pharmaceuticals by 28.6% during the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company’s stock worth $35,879,000 after acquiring an additional 144,214 shares during the last quarter. Finally, Barclays PLC raised its position in ANI Pharmaceuticals by 1,681.2% during the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after purchasing an additional 135,003 shares during the period. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.